NO20060374L - Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet - Google Patents

Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet

Info

Publication number
NO20060374L
NO20060374L NO20060374A NO20060374A NO20060374L NO 20060374 L NO20060374 L NO 20060374L NO 20060374 A NO20060374 A NO 20060374A NO 20060374 A NO20060374 A NO 20060374A NO 20060374 L NO20060374 L NO 20060374L
Authority
NO
Norway
Prior art keywords
immunomodulatory
inflammatory
peptidomimetics
peptides
compounds
Prior art date
Application number
NO20060374A
Other languages
English (en)
Inventor
Takumi Kawabe
Hidetaka Kobayashi
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of NO20060374L publication Critical patent/NO20060374L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Det tilveiebringes forbindelser med immunmodulerende og/eller antiinflammatorisk og/eller antiviral aktivitet der forbindelsene ifølge oppfinnelsen inkluderer peptider og peptidomimetika. Det tilveiebringes videre metoder for anvendelse av de immunmodulerende og/eller antiinflammatoriske og/eller antivirale forbindelser ifølge oppfinnelsen. Særlig tilveiebringer oppfinnelsen metoder for behandling av en sykdom relatert til en immunforstyrrelse, inflammasjon eller viralinfeksjon ved administrering av en mengde av et G2-kontrollpunktsabrogerende peptid eller peptidomimetikum tilstrekkelig til å inhibere sykdommen.
NO20060374A 2003-06-25 2006-01-24 Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet NO20060374L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48275003P 2003-06-25 2003-06-25
PCT/IB2004/002591 WO2004112820A2 (en) 2003-06-25 2004-06-25 Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity

Publications (1)

Publication Number Publication Date
NO20060374L true NO20060374L (no) 2006-03-20

Family

ID=33539355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060374A NO20060374L (no) 2003-06-25 2006-01-24 Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet

Country Status (10)

Country Link
US (2) US7479484B2 (no)
EP (1) EP1648490A2 (no)
JP (1) JP4705567B2 (no)
KR (1) KR20060065588A (no)
CN (1) CN1812805A (no)
AU (1) AU2004248998A1 (no)
CA (1) CA2530900A1 (no)
NO (1) NO20060374L (no)
WO (1) WO2004112820A2 (no)
ZA (1) ZA200510341B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1812805A (zh) * 2003-06-25 2006-08-02 坎巴斯有限公司 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物
WO2009038771A2 (en) * 2007-09-19 2009-03-26 Massachusetts Institute Of Technology Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers
WO2013167298A1 (en) 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
EP3013351B1 (en) * 2013-06-24 2019-10-30 CanBas Co., Ltd. Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
JP6466971B2 (ja) 2014-04-30 2019-02-06 ジェムバックス アンド カエル カンパニー，リミティド 臓器、組織又は細胞移植用組成物、キット及び移植方法
JP2017519185A (ja) * 2014-05-22 2017-07-13 株式会社 キャンバス Ｎｒｆ２をベースとした癌の治療方法及び検出方法並びに使用
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
KR102638286B1 (ko) * 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
CN108484745B (zh) * 2018-05-17 2021-06-25 青岛大学 一种小麦白粉病抗性相关蛋白TaSARD1及其编码基因与应用
KR102876070B1 (ko) * 2023-02-08 2025-10-24 웰펩 주식회사 신규 펩티도미메틱을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239268B1 (en) * 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
CA2216559A1 (en) * 1997-09-25 1999-03-25 Michel Roberge G2 checkpoint inhibitors and assay
JP4610828B2 (ja) * 1999-09-22 2011-01-12 株式会社 キャンバス Ｇ２期細胞周期停止の阻害、およびｄｎａ損傷剤に対する細胞感作のための組成物および方法
AU2001243226A1 (en) * 2000-02-25 2001-09-03 The Regents Of The University Of California Scytonemin and methods of using thereof
CN100360564C (zh) 2002-01-17 2008-01-09 坎巴斯有限公司 具有抗增殖活性和/或可增强核酸损伤剂或治疗的效果的肽和肽模拟物
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
CN1812805A (zh) * 2003-06-25 2006-08-02 坎巴斯有限公司 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物

Also Published As

Publication number Publication date
WO2004112820A2 (en) 2004-12-29
AU2004248998A1 (en) 2004-12-29
CA2530900A1 (en) 2004-12-29
WO2004112820A3 (en) 2005-04-28
KR20060065588A (ko) 2006-06-14
US20090192090A1 (en) 2009-07-30
US7479484B2 (en) 2009-01-20
JP2007521256A (ja) 2007-08-02
JP4705567B2 (ja) 2011-06-22
ZA200510341B (en) 2007-05-30
US20060003941A1 (en) 2006-01-05
CN1812805A (zh) 2006-08-02
EP1648490A2 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
NO20060374L (no) Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
DE69434181D1 (de) Therapeutische Peptid Derivate
DE60224419D1 (de) Von igf-bindungsprotein stammendes peptid
IL204453A (en) Use of human magic roundabout (mr), for the preparation of drugs to inhibit migration and / or proliferation of endothelial cells
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
TR199900694T2 (xx) �nsulin C-peptitleri.
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
DE60323333D1 (de) Fab-fragmente humaner monoklonaler antikörper mit protein
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
DE50205029D1 (de) Entzündungsspezifische peptide und deren verwendungen
CY1119819T1 (el) Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
ATE384078T1 (de) Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
ATE484290T1 (de) Peptid mit antitumoraler wirkung
ATE390440T1 (de) Neuroaktive peptide
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
WO2003072606A3 (en) Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
DE60321554D1 (de) Neue analoga von nitrobenzylthioinosin
ATE410448T1 (de) Neues peptid und pharmazeutische zusammensetzung, die dieses peptid enthält
BRPI0406985A (pt) Terapia de combinação de hcv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application